114 related articles for article (PubMed ID: 9193456)
1. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma.
Tsai JF; Chuang LY; Jeng JE; Yang ML; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Medicine (Baltimore); 1997 May; 76(3):213-26. PubMed ID: 9193456
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 75(10):1460-6. PubMed ID: 9166938
[TBL] [Abstract][Full Text] [Related]
3. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Yang ML; Ho MS; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Br J Cancer; 1997; 76(2):244-50. PubMed ID: 9231926
[TBL] [Abstract][Full Text] [Related]
4. Urinary transforming growth factor-beta 1 in relation to serum alpha-fetoprotein in hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; Chang WY; Hsieh MY; Lin ZY; Tsai JH
Scand J Gastroenterol; 1997 Mar; 32(3):254-60. PubMed ID: 9085463
[TBL] [Abstract][Full Text] [Related]
5. Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Yeh YC; Tsai JF; Chuang LY; Yeh HW; Tsai JH; Florine DL; Tam JP
Cancer Res; 1987 Feb; 47(3):896-901. PubMed ID: 2433030
[TBL] [Abstract][Full Text] [Related]
6. Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.
Jeng JE; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
Tumour Biol; 2014 Apr; 35(4):3689-98. PubMed ID: 24375326
[TBL] [Abstract][Full Text] [Related]
7. Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis.
Tomiya T; Fujiwara K
Cancer; 1996 Mar; 77(6):1056-60. PubMed ID: 8635123
[TBL] [Abstract][Full Text] [Related]
8. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases.
Shirai Y; Kawata S; Tamura S; Ito N; Tsushima H; Takaishi K; Kiso S; Matsuzawa Y
Cancer; 1994 May; 73(9):2275-9. PubMed ID: 7513247
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Ho MS; Chang WY; Lin ZY; Tsai JH
Br J Cancer; 1995 Aug; 72(2):442-6. PubMed ID: 7543774
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.
Yang SL; Liu LP; Yang S; Liu L; Ren JW; Fang X; Chen GG; Lai PB
Br J Surg; 2016 May; 103(6):716-724. PubMed ID: 26996727
[TBL] [Abstract][Full Text] [Related]
13. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma.
Ali MA; Koura BA; el-Mashad N; Zaghloul MH
Egypt J Immunol; 2004; 11(1):83-90. PubMed ID: 15724390
[TBL] [Abstract][Full Text] [Related]
14. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Ho MS; Lai CS; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Tumour Biol; 2003; 24(6):291-8. PubMed ID: 15004489
[TBL] [Abstract][Full Text] [Related]
17. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
18. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
19. Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia.
Yasmin Anum MY; Looi ML; Nor Aini AH; Merican I; Wahidah A; Mohd Radzi AH; Nor Azizah A; Othman NH
Med J Malaysia; 2009 Sep; 64(3):223-7. PubMed ID: 20527273
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
